Mani Foroohar
Stock Analyst at Leerink Partners
(0.14)
# 4,702
Out of 5,076 analysts
947
Total ratings
43.4%
Success rate
-5.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Reiterated: Hold | $4 | $2.29 | +74.67% | 57 | Oct 7, 2026 | |
| ENGN enGene Therapeutics | Reiterated: Hold | $2 | $1.56 | +28.21% | 14 | Sep 9, 2026 | |
| ABSI Absci | Initiated Coverage: Buy | $12 | $9.18 | +30.72% | 1 | Jun 4, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $100 → $154 | $80.39 | +91.57% | 54 | May 15, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $17 | $6.68 | +154.49% | 64 | May 15, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $27 → $35 | $11.21 | +212.22% | 52 | Apr 27, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | $8 → $9 | $3.30 | +172.73% | 7 | Apr 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Hold | n/a | $58.02 | - | 56 | Mar 26, 2026 | |
| MRNA Moderna | Reiterated: Sell | $12 | $200.10 | -94.00% | 89 | Feb 11, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Hold | $370 → $351 | $224.03 | +56.68% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $370 → $86 | $68.56 | +25.44% | 76 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 → $100 | $42.93 | +132.94% | 67 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 → $2 | $0.389 | +414.14% | 16 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $2.80 | n/a | 16 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 → $74 | $49.39 | n/a | 27 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.80 | n/a | 41 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.70 | n/a | 34 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 → $48 | $41.49 | n/a | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $8.65 | n/a | 9 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $24.05 | n/a | 20 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $27 | $23.80 | n/a | 12 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.5328 | n/a | 32 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $23.55 | n/a | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $2.40 | n/a | 20 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $1.87 | n/a | 31 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.40 | n/a | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $3.16 | n/a | 15 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $35.32 | n/a | 1 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $5 | $3.18 | n/a | 24 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $6 | $4.40 | n/a | 17 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $20.07 | n/a | 7 | Oct 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $216 → $197 | $17.73 | n/a | 3 | Nov 6, 2020 |
Rocket Pharmaceuticals
Oct 7, 2026
Reiterated: Hold
Price Target: $4
Current: $2.29
Upside: +74.67%
enGene Therapeutics
Sep 9, 2026
Reiterated: Hold
Price Target: $2
Current: $1.56
Upside: +28.21%
Absci
Jun 4, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $9.18
Upside: +30.72%
Mirum Pharmaceuticals
May 15, 2026
Reiterated: Buy
Price Target: $100 → $154
Current: $80.39
Upside: +91.57%
REGENXBIO
May 15, 2026
Reiterated: Buy
Price Target: $17
Current: $6.68
Upside: +154.49%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $27 → $35
Current: $11.21
Upside: +212.22%
Camp4 Therapeutics
Apr 2, 2026
Reiterated: Buy
Price Target: $8 → $9
Current: $3.30
Upside: +172.73%
Arrowhead Pharmaceuticals
Mar 26, 2026
Reiterated: Hold
Price Target: n/a
Current: $58.02
Upside: -
Moderna
Feb 11, 2026
Reiterated: Sell
Price Target: $12
Current: $200.10
Upside: -94.00%
Alnylam Pharmaceuticals
Dec 15, 2025
Reiterated: Hold
Price Target: $370 → $351
Current: $224.03
Upside: +56.68%
Dec 15, 2025
Reiterated: Buy
Price Target: $370 → $86
Current: $68.56
Upside: +25.44%
Dec 15, 2025
Reiterated: Buy
Price Target: $68 → $100
Current: $42.93
Upside: +132.94%
Dec 15, 2025
Reiterated: Buy
Price Target: $3 → $2
Current: $0.389
Upside: +414.14%
Oct 21, 2025
Reiterated: Buy
Price Target: $20 → $18
Current: $2.80
Upside: n/a
Oct 15, 2025
Reiterated: Buy
Price Target: $56 → $74
Current: $49.39
Upside: n/a
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $10.80
Upside: n/a
Oct 15, 2025
Reiterated: Hold
Price Target: n/a
Current: $3.70
Upside: n/a
Sep 25, 2025
Reiterated: Buy
Price Target: $51 → $48
Current: $41.49
Upside: n/a
Sep 23, 2025
Reiterated: Buy
Price Target: $20
Current: $8.65
Upside: n/a
Sep 3, 2025
Reiterated: Buy
Price Target: n/a
Current: $24.05
Upside: n/a
Aug 18, 2025
Reiterated: Buy
Price Target: $32 → $27
Current: $23.80
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $3
Current: $0.5328
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: $70
Current: $23.55
Upside: n/a
Mar 6, 2025
Reiterated: Hold
Price Target: $1
Current: $2.40
Upside: n/a
Aug 9, 2024
Reiterated: Hold
Price Target: $1
Current: $1.87
Upside: n/a
Jul 15, 2024
Reiterated: Buy
Price Target: n/a
Current: $8.40
Upside: n/a
Nov 13, 2023
Reiterated: Hold
Price Target: $21
Current: $3.16
Upside: n/a
Jun 8, 2023
Reiterated: Sell
Price Target: n/a
Current: $35.32
Upside: n/a
May 23, 2023
Reiterated: Hold
Price Target: $6 → $5
Current: $3.18
Upside: n/a
Nov 14, 2022
Reiterated: Hold
Price Target: $5 → $6
Current: $4.40
Upside: n/a
Oct 19, 2021
Reiterated: Hold
Price Target: n/a
Current: $20.07
Upside: n/a
Nov 6, 2020
Reiterated: Buy
Price Target: $216 → $197
Current: $17.73
Upside: n/a